- Home
- DTIL vs LEXX Comparison
DTIL vs LEXX Comparison
Compare DTIL & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTIL
- LEXX
- Stock Information
- Founded
- DTIL 2006
- LEXX 2004
- Country
- DTIL United States
- LEXX Canada
- Employees
- DTIL N/A
- LEXX N/A
- Industry
- DTIL Biotechnology: Pharmaceutical Preparations
- LEXX Biotechnology: Pharmaceutical Preparations
- Sector
- DTIL Health Care
- LEXX Health Care
- Exchange
- DTIL Nasdaq
- LEXX Nasdaq
- Market Cap
- DTIL 44.1M
- LEXX 43.5M
- IPO Year
- DTIL 2019
- LEXX N/A
- Fundamental
- Price
- DTIL $4.51
- LEXX $2.16
- Analyst Decision
- DTIL Strong Buy
- LEXX Strong Buy
- Analyst Count
- DTIL 2
- LEXX 2
- Target Price
- DTIL $39.50
- LEXX $11.00
- AVG Volume (30 Days)
- DTIL 104.8K
- LEXX 192.0K
- Earning Date
- DTIL 11-04-2024
- LEXX 01-10-2025
- Dividend Yield
- DTIL N/A
- LEXX N/A
- EPS Growth
- DTIL N/A
- LEXX N/A
- EPS
- DTIL 1.45
- LEXX N/A
- Revenue
- DTIL $75,096,000.00
- LEXX $464,278.00
- Revenue This Year
- DTIL $50.33
- LEXX $73.01
- Revenue Next Year
- DTIL N/A
- LEXX $48.40
- P/E Ratio
- DTIL $3.21
- LEXX N/A
- Revenue Growth
- DTIL 43.62
- LEXX 105.24
- 52 Week Low
- DTIL $4.56
- LEXX $1.20
- 52 Week High
- DTIL $19.43
- LEXX $6.85
- Technical
- Relative Strength Index (RSI)
- DTIL 24.26
- LEXX 41.53
- Support Level
- DTIL $5.12
- LEXX $2.00
- Resistance Level
- DTIL $6.18
- LEXX $2.54
- Average True Range (ATR)
- DTIL 0.46
- LEXX 0.25
- MACD
- DTIL -0.13
- LEXX -0.01
- Stochastic Oscillator
- DTIL 5.21
- LEXX 12.94
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.